(Q39915376)

15 September 2017

In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies (English)

1 reference

15 September 2017

5

Peter Nygren

1 reference

15 September 2017

4

Rolf Larsson

1 reference

15 September 2017

3

Anna Aleskog

1 reference

15 September 2017

Kristina Wiberg

1

1 reference

PubMed ID

19016012

15 September 2017

Kristina Carlson

series ordinal

2

1 reference

PubMed ID

19016012

15 September 2017

Elin Lindhagen

series ordinal

6

1 reference

15 September 2017

18 November 2008

1 reference

15 September 2017

1 reference

15 September 2017

26

1 reference

15 September 2017

2

1 reference

15 September 2017

193-201

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-008-9107-6

15 September 2017

0 references

cites work

Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-008-9107-6

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-008-9107-6

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

12 December 2020

Proteasome inhibition in the treatment of cancer

1 reference

12 December 2020

Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro

1 reference

12 December 2020

Predictive tests for individualization of pharmacological cancer treatment

1 reference

12 December 2020

Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients

1 reference

12 December 2020

Proteasome inhibition: a new strategy in cancer treatment

1 reference

12 December 2020

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

1 reference

12 December 2020

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

1 reference

12 December 2020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

12 December 2020

Isobolographic analysis for combinations of a full and partial agonist: curved isoboles

1 reference

12 December 2020

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

1 reference

12 December 2020

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma

1 reference

12 December 2020

Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).

1 reference

12 December 2020

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors

1 reference

12 December 2020

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

1 reference

12 December 2020

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

1 reference

12 December 2020

Testing chemotherapeutic combinations in the human tumor colony—forming assay

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

1 reference

12 December 2020

Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic

1 reference

12 December 2020

Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models

1 reference

12 December 2020

In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells

1 reference

12 December 2020

Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells

1 reference

12 December 2020

Screening of an annotated compound library for drug activity in a resistant myeloma cell line

1 reference

12 December 2020

Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA)

1 reference

12 December 2020

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

12 December 2020

The proteasome and proteasome inhibitors in cancer therapy

1 reference

12 December 2020

Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

1 reference

12 December 2020

The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate

1 reference

12 December 2020

10.1007/S12032-008-9107-6

Identifiers

DOI

1 reference

15 September 2017

1 reference

PubMed ID

19016012